Financial & Policy Research Insights

A potential shift in UK drug pricing policy may open new revenue opportunities for pharma manufacturers amid trade negotiations with the U.S.

Get expert insights into how policy risks, patent cliffs, AI innovation, and tariffs are reshaping the biopharma sector in 2025.

Explore how legislative shifts, funding cuts, and court rulings are reshaping ACA coverage, premiums, and insurer margins—plus what’s next for HSAs and ICHRAs in 2025 and beyond.

CFRA’s latest stock report on UnitedHealth Group ($UNH) outlines a sharp downgrade to Sell amid DOJ fraud investigations and reduced earnings guidance.

Why New State Legislation Could Upend Business Models for CTRE, MPW, OHI, SBRA, and WELL.

In the first 100 days of the Trump administration, healthcare has shifted...

This exclusive Washington Analysis call explored the Trump administration’s food policy priorities, featuring an experienced regulatory attorney.

This research explores how potential PBM reform, IRA implementation, and pricing policy shifts may provide moderate tailwinds for retail pharmacy chains like CVS, WBA, and RiteAid in 2025.

Washington Analysis Healthcare Team hosted a conference call with a leading UK-based strategic advisor to understand better the potential...

An exclusive policy event in Washington, D.C., covering key legislative developments in healthcare, consumer goods, Medicaid, Medicare, and RFK Jr.'s Make America Healthy Again priorities.